Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)Article Published on 2022-09-212022-11-15 Journal: BMC Infectious Diseases [Category] SARS, 진단, 치료기술, [키워드] age analyzed anti-SARS-CoV-2 Anti-spike Antiretroviral therapy black BNT162b2 booster CD4 CD8 cells clinically COVID-19 COVID-19 vaccination COVID-19 vaccine decrease demographics detectable dose exploratory female HIV Humoral immunity IgG IgG levels immune response immunogenicity majority male marker median MOST occurred offered Older outcome participant positive presenting primary analysis protective immunity quantitative assessment reactogenicity recruited responses SARS-CoV-2 secondary single-center Spike protein subject suppressed T-cell T-cell Response vaccination Viremia virus-specific T-cell response white Wilcoxon signed-rank test with HIV [DOI] 10.1186/s12879-022-07737-0 PMC 바로가기
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiencyArticle Published on 2022-09-142022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료기술, [키워드] activity Adverse reaction analyzed Anti-SARS-CoV-2 S antibody Antibody Response Autoimmune Autoimmune diseases B-lymphocytes Cell Cohort cohort of patient comparable Course COVID-19 COVID-19 vaccination CVID deficiency detect Disease activity dysfunction effective Efficacy and safety Elecsy flow cytometry healthy control humoral humoral immune response Hypogammaglobulinemia IFN-gamma immune system Immunity immunization immunoassay immunodeficiency immunoglobulin replacement therapy in healthy individuals increased risk individual Interferon-gamma lymphocyte neutralization Patient Phenotyping pneumococcal provide reactogenicity receptor Safe SARS-COV-2 infection selective Seven subjects Support syndrome T cell response T-lymphocites the disease triggering underlying disease vaccination vaccine response Vero E6 Virus neutralization was performed well X-linked agammaglobulinemia XLA [DOI] 10.3389/fimmu.2022.974987 PMC 바로가기
A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospectsArticle Published on 2022-09-132022-11-16 Journal: Frontiers in Immunology [Category] SARS, 변종, [키워드] Administered Adults age antigenic approved booster children clinical development comparable country CoV COVID-19 pandemic COVID-19 severity disease Effectiveness Efficacy Emergency use Emergency use authorization generate geometric mean titer group Healthcare system Heterologous heterologous prime and boost vaccines heterologous prime-boost immune response inactivated Inactivated vaccine inactivated virus adjuvanted vaccine increase in India induce Like memory B morbidity Mortality neutralization neutralization titer original antigenic sin over pandemic pediatric phase Population prime and boost reactogenicity reduce reduction in robust safety profile SARS – CoV – 2 SARS-CoV-2 variant seroconversion rate symptomatic COVID-19 disease synergy T-cell responses TLR7/8 vaccinated individuals vaccination Vaccine vaccine challenges Vaccine development vaccine dose Vaccines variants of concern variants of concern (VOCs) virus VOCs waning immunity [DOI] 10.3389/fimmu.2022.940715 PMC 바로가기
COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19Article Published on 2022-09-022022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] adverse event adverse events anti-S IgG antibody association blood sample BNT162b2 ChAdOx1 nCoV-19 coronavirus disease COVID-19 COVID-19 vaccine cytokine dose elevated enrolled evaluated Fever GRADE healthy humoral immune responses IgG IL-1β IL-6 immunogenicity Inflammatory Inflammatory responses neutralizing antibody responses Neutralizing antibody titer of BNT162b2 opposite participant positively correlated Proinflammatory cytokine reaction reactogenicity recipient recipients response responses resulting second dose significantly systemic systemic adverse event the median vaccination Vaccine vaccine platform vaccine-induced immune response Vaccines [DOI] 10.3389/fimmu.2022.975363 PMC 바로가기
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 studyClinical Trial Published on 2022-09-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI Administered Adults adverse event age all age group antibody baseline Bharat Biodefense children clinical conducted COVID-19 vaccine curtail deaths decrease demonstrated dose Efficacy eight eligible Endpoint enrolled female Fever for inclusion geometric mean GMT ratio GMTs group groups healthy children hospital Hyderabad immunogenicity immunosuppressive inactivated Inactivated vaccine India Infection injection site pain intramuscular dose less Local local reaction male Mild Mild-to-moderate multicentre neutralisation test neutralising antibody response neutralising antibody titre no difference Open-label Pain pandemic participant Phase 2 study phase 2/3 platform positive PRNT Reactions reactogenicity reduction Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine second dose Serious Adverse Events seroconverted serology test serum sample severity of COVID-19 susceptible Symptom three group titre Trial were excluded Withdrawal [DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccinationArticle Published on 2022-09-012022-10-06 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, [키워드] Anti-spike antibodies Antibody Response benefit BNT162b2 comparable develop dose evaluate event Heterologous homologous IMPROVE mRNA vaccination mRNA vaccine mRNA vaccines naïve Poisson regression reactogenicity recipient recipients remained SARS-CoV-2 SARS-CoV-2 vaccine Seroconversion seroconvert seronegative solid organ transplant Tolerability Transplant vaccination Vaccine [DOI] 10.1111/ajt.17061 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial말라위에서 9개월에서 12세 사이의 어린이를 대상으로 한 장티푸스 접합 백신의 안전성 및 면역원성: 이중 맹검, 무작위 대조 시험의 중첩 하위 연구Clinical Trial Published on 2022-09-012022-09-12 Journal: The Lancet. Global health [Category] Fulltext, MERS, 살모넬라증, 임상, 진단, [키워드] 1:1 95% CI adverse event age analysed antibody assigned baseline children chronic health conditions clinical trial COVID-19 double-blind eight eligible eligible participant ELISA enrolled evaluated Evidence foundation geometric mean titre HIV IgG Immunosuppression intention-to-treat population intramuscularly Local Melinda Gate occurred outcomes participant Phase 3 provide public health randomised controlled trial Randomly reactogenicity receive recipient recipients Registered remained Safety screened titre Tolerability Trial typhoid fever vaccination Vaccine was collected [DOI] 10.1016/S2214-109X(22)00275-3 PMC 바로가기 [Article Type] Clinical Trial
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccineArticle Published on 2022-09-012022-10-05 Journal: Vaccine [Category] SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술, [키워드] Antibody Response approved BNT162b2 booster booster dose clinical trial comparable CoronaVac coronavirus disease Coverage COVID-19 COVID-19 vaccine Delta diarrhea dose elicited groups headache healthcare healthy heterologous vaccine Inactivated vaccine joint mRNA mRNA vaccine mRNA-1273 vaccine omicron Omicron variant Pain pandemic reactogenicity reduced Reduced dose Result significant difference Standard dose the SARS-CoV-2 third dose Vaccine World Health Organization [DOI] 10.1016/j.vaccine.2022.08.033 [Article Type] Article
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccinationArticle Published on 2022-09-012022-10-05 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, [키워드] Administered Adverse Anti-RBD IgG AZD1222 binding BNT162b2 boost booster booster vaccination Booster vaccine cellular response COVID-19 COVID-19 vaccines domain dose elicited enrolled evade event Evidence healthy Heterologous heterologous booster highest homologous homologous or heterologous humoral Immunity Immunoglobulin individual individuals Messenger RNA mRNA mRNA-1273 Mutation NAb NAbs neutralization neutralizing antibody objective omicron overcome participant peaked persistence provided RBD reactogenicity reduction Result SARS-CoV-2 significantly T cell response T cells Total vaccination Vaccinations Vaccine vaccine dose Vaccines variant variants waning immunity [DOI] 10.1016/j.ijid.2022.07.038 [Article Type] Article
Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV 및 mRNA-1273을 사용한 SARS CoV-2에 대한 이종 면역의 면역원성과 반응성Article Published on 2022-08-162022-09-11 Journal: Cell Reports Medicine [Category] SARS, 변종, 진단, 치료기술, [키워드] Ad5-nCoV analyzed Anti-spike Antibody Response BBIBP-CorV ChAdOx1 ChAdOx1 vaccine ChAdOx1-S Cohort Combination coronavirus disease Coronavirus disease 2019 Coverage COVID-19 evaluate Heterologous heterologous vaccination heterologous vaccine highest homologous humoral Humoral response IgG immunization immunogenicity Immunoglobulin Immunoglobulin G information Messenger RNA mRNA mRNA-1273 nCoV Neutralizing antibodies observation observé omicron Omicron variant Participants platform provide reactogenicity Region SARS CoV-2 SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events Sputnik V Support titers vaccination Vaccine virus neutralizing titer virus neutralizing titers [DOI] 10.1016/j.xcrm.2022.100706 PMC 바로가기 [Article Type] Article